Y Mabs Therapeutics Stock Analysis
YMAB Stock | USD 5.56 0.14 2.58% |
Y mAbs Therapeutics is undervalued with Real Value of 9.18 and Target Price of 20.36. The main objective of Y MAbs stock analysis is to determine its intrinsic value, which is an estimate of what Y mAbs Therapeutics is worth, separate from its market price. There are two main types of Y MAbs' stock analysis: fundamental analysis and technical analysis.
The Y MAbs stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Y MAbs' ongoing operational relationships across important fundamental and technical indicators.
YMAB |
YMAB Stock Analysis Notes
About 12.0% of the company outstanding shares are owned by insiders. The book value of Y MAbs was at this time reported as 2.07. The company has Price/Earnings To Growth (PEG) ratio of 0.04. Y mAbs Therapeutics recorded a loss per share of 0.54. The entity had not issued any dividends in recent years. Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Y-Mabs Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people. For more information please call Michael Rossi at 646 885 8505 or visit https://www.ymabs.com.Y mAbs Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Y MAbs' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Y mAbs Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Y mAbs Therapeutics generated a negative expected return over the last 90 days | |
Y mAbs Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 84.82 M. Net Loss for the year was (21.43 M) with profit before overhead, payroll, taxes, and interest of 75.11 M. | |
Y mAbs Therapeutics currently holds about 133.66 M in cash with (27.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.06. | |
Y mAbs Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 73.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from news.google.com: Y-mAbs Therapeutics to Release Earnings on Tuesday - MarketBeat |
Y mAbs Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Y MAbs previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
YMAB Largest EPS Surprises
Earnings surprises can significantly impact Y MAbs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-11-04 | 2021-09-30 | -0.6 | -0.66 | -0.06 | 10 | ||
2019-05-10 | 2019-03-31 | -0.41 | -0.47 | -0.06 | 14 | ||
2018-11-13 | 2018-09-30 | -0.36 | -0.42 | -0.06 | 16 |
Y MAbs Environmental, Social, and Governance (ESG) Scores
Y MAbs' ESG score is a quantitative measure that evaluates Y MAbs' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Y MAbs' operations that may have significant financial implications and affect Y MAbs' stock price as well as guide investors towards more socially responsible investments.
YMAB Stock Institutional Investors
Shares | D. E. Shaw & Co Lp | 2024-12-31 | 615.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 463.2 K | Cormorant Asset Management, Llc | 2024-12-31 | 425 K | Northern Trust Corp | 2024-12-31 | 359.2 K | Soleus Capital Management, L.p. | 2024-12-31 | 350 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 320.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 284.5 K | Citadel Advisors Llc | 2024-12-31 | 221.9 K | Goldman Sachs Group Inc | 2024-12-31 | 219.2 K | Paradigm Biocapital Advisors Lp | 2024-12-31 | 4.2 M | Blackrock Inc | 2024-12-31 | 3 M |
YMAB Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 249.03 M.YMAB Profitablity
The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.43) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.43.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.15) | (0.16) | |
Return On Capital Employed | (0.21) | (0.23) | |
Return On Assets | (0.15) | (0.16) | |
Return On Equity | (0.19) | (0.20) |
Management Efficiency
Y mAbs Therapeutics has return on total asset (ROA) of (0.1198) % which means that it has lost $0.1198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Y MAbs' management efficiency ratios could be used to measure how well Y MAbs manages its routine affairs as well as how well it operates its assets and liabilities. As of March 3, 2025, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Y MAbs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 129.5 M, whereas Other Current Assets are forecasted to decline to about 4.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.08 | 2.50 | |
Tangible Book Value Per Share | 2.03 | 2.48 | |
Enterprise Value Over EBITDA | (7.96) | (8.35) | |
Price Book Value Ratio | 3.39 | 3.22 | |
Enterprise Value Multiple | (7.96) | (8.35) | |
Price Fair Value | 3.39 | 3.22 | |
Enterprise Value | 253.5 M | 240.8 M |
Evaluating the management effectiveness of Y MAbs allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The YMAB Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 3rd of March, Y MAbs maintains the Mean Deviation of 2.53, standard deviation of 3.33, and Market Risk Adjusted Performance of (0.65). Compared to fundamental indicators, the technical analysis model lets you check practical technical drivers of Y mAbs Therapeutics, as well as the relationship between them.Y mAbs Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Y MAbs middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Y mAbs Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Y mAbs Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Y MAbs insiders, such as employees or executives, is commonly permitted as long as it does not rely on Y MAbs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Y MAbs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Y MAbs Outstanding Bonds
Y MAbs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Y mAbs Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most YMAB bonds can be classified according to their maturity, which is the date when Y mAbs Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
US98420EAB11 Corp BondUS98420EAB11 | View | |
XEROX HLDGS P Corp BondUS98421MAB28 | View | |
XEROX HLDGS P Corp BondUS98421MAA45 | View |
Y MAbs Predictive Daily Indicators
Y MAbs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Y MAbs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Y MAbs Corporate Filings
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 17th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F3 | 16th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Y MAbs Forecast Models
Y MAbs' time-series forecasting models are one of many Y MAbs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Y MAbs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About YMAB Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Y MAbs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling YMAB shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Y MAbs. By using and applying YMAB Stock analysis, traders can create a robust methodology for identifying YMAB entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.22) | (0.23) | |
Operating Profit Margin | (0.27) | (0.29) | |
Net Loss | (0.23) | (0.24) | |
Gross Profit Margin | 1.00 | 0.98 |
Current YMAB Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. YMAB analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. YMAB analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
20.36 | Strong Buy | 11 | Odds |
Most YMAB analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand YMAB stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Y mAbs Therapeutics, talking to its executives and customers, or listening to YMAB conference calls.
YMAB Stock Analysis Indicators
Y mAbs Therapeutics stock analysis indicators help investors evaluate how Y MAbs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Y MAbs shares will generate the highest return on investment. By understating and applying Y MAbs stock analysis, traders can identify Y MAbs position entry and exit signals to maximize returns.
Begin Period Cash Flow | 105.8 M | |
Common Stock Shares Outstanding | 43.6 M | |
Total Stockholder Equity | 101 M | |
Tax Provision | 561 K | |
Property Plant And Equipment Net | 1.6 M | |
Cash And Short Term Investments | 78.6 M | |
Cash | 78.6 M | |
Accounts Payable | 6.1 M | |
Net Debt | -77.2 M | |
50 Day M A | 6.7688 | |
Total Current Liabilities | 20.1 M | |
Other Operating Expenses | 110.5 M | |
Non Current Assets Total | 16.8 M | |
Forward Price Earnings | 119.0476 | |
Non Currrent Assets Other | 12.5 M | |
Stock Based Compensation | 14.5 M |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |